My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Sci Transl Med. 2010 Jun 2;2(34):34ps27.

    Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials.

    Sikorski R, Yao B.

    Source

    Amgen, Thousand Oaks, CA 91320, USA. public@robertsikorski.com

    Abstract

    Selection biomarkers are disease-associated analytes whose measurement is either an essential step in patient screening or the primary objective of a clinical trial. The public database ClinicalTrials.gov contains information on most active phase III oncology clinical trials that can be examined for trends in the development of cancer therapies. But for selection biomarkers, such information is not easily accessible and so has not been examined in a comprehensive way. Here we provide a global analysis of selection biomarkers currently in use in the oncology phase III trial arena.

    PMID:
    20519717
    [PubMed - indexed for MEDLINE]

    MeSH Terms, Substances

    MeSH Terms

    Substances

    LinkOut - more resources

    Full Text Sources

    Other Literature Sources

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Related citations in PubMed

      See reviews... See all...

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk